Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enoxaparin Prophylactic vs Therapeutic Dose in COVID-19
NCT04646655Phase 3Completed
- Sponsor
- ASST Fatebenefratelli Sacco
- Start
- Jul 2020
- Primary completion
- Oct 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of enoxaparin in coronavirus disease 2019 (COVID-19), sponsored by ASST Fatebenefratelli Sacco. Started Jul 2020; status: completed.
02
Drugs
enoxaparin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04646655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04646655.